News

Arvinas to Showcase Vepdegestrant Data at Major Oncology Event

Arvinas to Showcase Vepdegestrant Data at Major Oncology Event

Presentation of Vepdegestrant Data

Arvinas, Inc. (NASDAQ: ARVN) is set to present significant findings related to its investigational drug, vepdegestrant, at the European Society for Medical Oncology Congress. This event takes place in Berlin, from October 17 to 21, where new patient-reported outcomes from the Phase 3 VERITAC-2 trial will be shared.

Details of the Clinical Study

The first presentation will focus on the comparison of patient-reported outcomes (PROs) between vepdegestrant and fulvestrant, specifically in patients with estrogen receptor 1 gene mutations and advanced breast cancer. Dr. Mario Campone will serve as the presenting author during a mini oral session, scheduled for October 20, at 11:25 CEST.

Presentation Highlights

Entitled "Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/HER2? advanced breast cancer in the phase 3 VERITAC-2 trial," this report aims to showcase the potential efficacy of vepdegestrant. Presentation Number 489MO will provide insights into how this novel treatment method compares to existing therapy.

Second Study Presented

Additionally, another abstract will explore a phase 2 study of neoadjuvant vepdegestrant, comparing it with anastrozole in postmenopausal patients with localized breast cancer. This session will take place on October 19, with Dr. Peter A. Fasching as the presenting author.

About Vepdegestrant

Vepdegestrant is a unique PROTAC estrogen receptor degrader under development by Arvinas, designed to treat patients with estrogen receptor-positive breast cancer possessing specific genetic mutations. This work is part of Arvinas' expanding portfolio of innovative therapies targeting unmet medical needs for cancer patients.

Collaboration with Pfizer

In July 2021, Arvinas announced a significant partnership with Pfizer to co-develop and commercialize vepdegestrant. In an important update in September 2025, both companies revealed their intention to seek a third-party partner for the out-licensing and commercialization of this promising drug.

FDA's Endorsement

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant as a monotherapy for adults with estrogen receptor-positive, HER2-negative breast cancer. This designation, coupled with the FDA's Fast Track status, underlines the potential of vepdegestrant to become a preferred treatment option for patients who have undergone prior endocrine therapy.

About Arvinas, Inc.

Headquartered in New Haven, Connecticut, Arvinas (NASDAQ: ARVN) focuses on developing transformative therapies for patients with serious diseases. Utilizing its proprietary PROTAC technology, the company aims to revolutionize how therapies are delivered, with several investigational drugs undergoing clinical trials targeting key oncological and neurodegenerative conditions.

Frequently Asked Questions

What is vepdegestrant?

Vepdegestrant is an investigational drug designed as a PROTAC estrogen receptor degrader, targeting specific mutations in breast cancer.

When will the data from the clinical trials be presented?

The data will be presented during the European Society for Medical Oncology Congress, from October 17 to 21.

Who is leading the presentations at the Congress?

Dr. Mario Campone will present the findings from the VERITAC-2 trial.

What does the collaboration with Pfizer involve?

The partnership with Pfizer focuses on the co-development and commercialization of vepdegestrant.

What is the FDA's stance on vepdegestrant?

The FDA has accepted the NDA for vepdegestrant and granted it Fast Track designation.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 134

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 174

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 132

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 82

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 108

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 118

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 98

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading

Top 5 Most Recently Viewed Articles

Aramore: Recognized as a Leader in Wellness Innovation

Updated Category News Views 276

Aramore Wins Prestigious Award for Innovation in Wellness A significant milestone in the beauty and wellness sector has been marked by Aramore's recent recognition as the "Best Breakthrough Wellness Startup" in the 2025 Glossy Awards. This honor underlines the company’s groundbreaking scientific approach to skin care and health enhancement, setting a new standard for...

Continue Reading
GAPVelocity AI: Pioneering Hybrid Approach to Legacy Modernization

Updated Category News Views 244

Transforming Legacy Modernization with GAPVelocity AI Industry-First Combination of Deterministic and Generative AI Delivers 75% Faster Modernization with Enterprise-Grade Security and Predictability Growth Acceleration Partners (GAP), a prominent consulting and technology services provider, has unveiled a revolutionary hybrid AI platform known as GAPVelocity AI. This...

Continue Reading
Singapore AI Week: A Gathering of Global AI Innovators

Updated Category News Views 311

Singapore AI Week: An Unforgettable Celebration Singapore AI Week is set to be a remarkable event, bringing together over 100 activities within 10 distinctive Community Hubs. This vibrant festival will feature an array of offerings, from Mixmag's creative-tech stage to the engaging student programs guided by the National Youth Council and Wavesparks. This event aims to...

Continue Reading
Cove Capital Hits Milestone: Debt-Free DST Success

Updated Category News Views 61

Unpacking Cove Capital's Latest Triumph Let’s dive right into this one. Cove Capital Investments isn’t playing around with their recent accomplishment. They’ve gone ahead and fully subscribed their latest playground for investors, the Ponder Small Bay Industrial 101 Delaware Statutory Trust. What makes this interesting is not just the $18.6 million in equity they...

Continue Reading
ZIM Integrated Shipping Services: A New Chapter Ahead

Updated Category News Views 252

ZIM Integrated Shipping Services Shares Are Making Headlines ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is in the spotlight as shares have seen fluctuations recently, especially after a dip of 1.13% in after-hours trading, closing at $19.29. Strategic Acquisition Proposal Under Review The board of ZIM is currently engaged in a comprehensive strategic review...

Continue Reading